|1.||WO||WO/2014/190953 - PROSTHETIC SYSTEM FOR REPLACING THE OSSICLES OF THE MIDDLE EAR||04.12.2014||
||PCT/CU2014/000002||CENTRO DE NEUROCIENCIAS DE CUBA (NEURONIC)||GONZALEZ SANTOS, Ramòn|
The invention concerns a prosthetic system for replacing the ossicles of the middle ear, designed both for partial (anvil or stirrup) and total (both components) replacement of the chain of ossicles of the middle ear, in order to restore hearing in patients suffering from a loss of hearing for this reason. The system is produced preferably from biocompatible photopolymers of which the bioactivity is increased by the addition of micro- and nanoparticles of calcium carbonates, phosphates, hydroxide, titanium oxide, hydroxyapatite and carbonate apatite, or a mixture thereof. It is thus possible to monitor the patients post-operatively, using any of the imaging technologies since the density of the material from which the prosthetic system is produced is very similar to that of bone. In all cases, complete stability of the implant can be attained by securing it by way of a fastener system, complemented if necessary with a cementing substance which is biocompatible with the bone.
|2.||WO||WO/2014/131374 - CHEMICAL CHAPERONINS AS NOVEL MOLECULAR MODULATORS OF BETA PROTEIN AGGREGATION PRESENT IN CONFORMATIONAL DISEASES||04.09.2014||
|PCT/CU2013/000009||CENTRO DE NEUROCIENCIAS DE CUBA (NEURONIC)||SABLON CARRAZANA, Marquiza|
The invention relates to chemistry and biochemistry applied to the field of medicine, and particularly to a novel method for the prevention and therapeutic treatment of conformational diseases (CD), especially diseases of an amyloid origin, by means of the administration of an effective quantity of at least one compound, the salts, prodrugs or solvates thereof, considered in this invention as chemical chaperonins, of formula I wherein: R1 is -alkylenyl-C(O)NH-alkylenyl-R3, -alkylenyl-C(O)O-R4; R3 is -COOH, -OH, -SH, -NH2, -NH-alkyl, -NH-alkyl dithiocarbamate, -N/-(alkyl)-dithiocarbamate of salts of alkaline earth metals or salts of the previously related groups, that are pharmaceutically acceptable, for the treatment of amyloidogenic diseases; R4 is a succinimide group; and R2 is -H, -alkyl.
|3.||WO||WO/2014/131375 - PHOTOPOLYMERISABLE COMPOSITE BIOMATERIALS FOR 3D PRINTING OF IMPLANTS||04.09.2014||
||PCT/CU2014/000001||CENTRO DE NEUROCIENCIAS DE CUBA (NEURONIC)||GONZALEZ SANTOS, Ramón|
The invention relates to photopolymerisable composite biomaterials for 3D printing of implants, formed by biocompatible mixtures of polymers derived from urethane dimethacrylate (UDMA), tetrahydrofurfuryl methacrylate (THFMA), methyl methacrylate (MMA), methyl polymethylmethacrylate (PMMA), 2-hydroxyethyl methacrylate (HEMA), neopentylglycol diacrylate propoxylate(NPGDP), vinyl acetate (VAc) and polyvinyl acetate (PVAc) combined with photoinitiators and mixtures of nano and microparticles of inorganic composites of hydroxycarbonate phosphates of calcium and titanium oxide. The mixtures are used as a printing material in the 3D printers which are operated by means of photopolymerisation using ultraviolet-visible light (stereolithography) and allow the exact reproduction or printing of virtual solid images of parts of tissues and organs made by means of computer-assisted design (CAD) or generated or reproduced from medical images such as CAT, NMR and others. The products obtained when polymerised with ultraviolet-visible radiation have suitable mechanical and biocompatibility properties for producing implantable medical devices by means of stereolithography 3D printing.
|4.||WO||WO/2014/101903 - DENGUE VIRUS VACCINE COMPOSITION||03.07.2014||
|PCT/CU2013/000008||CENTRO DE INGENIRIA GENETICA Y BIOTECNOLOGIA||HERMIDA CRUZ, Lisset|
Vaccine compositions that comprise at least one antigen based on the dengue virus (DV) capsid protein and the oligonucleotide identified as SEQ ID NO 1. The vaccine composition that comprises a fusion protein formed by the DV2 capsid and domain III of the envelope protein of the same serotype, together with the oligonucleotide identified as SEQ ID NO 1, gives rise to higher levels of cellular immune response and protection in mice as compared with that produced by formulations of the same antigen together with oligonucleotides with potential adjuvant capacity which were reported previously. The efficacy of the compositions that comprise the SEQ ID NO 1 oligonucleotide has been demonstrated in non-human primates. These compositions may be monovalent, bivalent or tetravalent and are combined in different immunization regimes with a view to inducing a functional immune response to the four viral serotypes.
|5.||WO||WO/2014/071894 - POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOF||15.05.2014||
|PCT/CU2013/000007||CENTRO DE INMUNOLOGIA MOLECULAR||CORRIA OSORIO, Ángel de Jesús|
The invention relates to branches of biotechnology and, in particular, to mutated polypeptides of the TGFß molecule, the primary sequence of which is highly homologous with the sequence of human TGFß. These muteins lose their ability to interact with ALK5 but retain their ability to interact with the rest of the receptors that form part of the receptor complex (TßRII and TßRIII). In addition, they can antagonise the signalling of all of the natural variants of the TGFß ligands, dependent on the recruitment of ALK5 in the receptor complex, and they have an immunomodulatory effect. The invention also relates to pharmaceutical compositions comprising, as active principle, the disclosed polypeptides or fusion proteins and to the therapeutic use of the disclosed polypeptides, fusion proteins and pharmaceutical compositions owing to their immunomodulatory effect on diseases such as cancer, diseases associated with fibrosis and chronic infectious diseases.
|6.||WO||WO/2014/067498 - CHIMERIC VACCINE ANTIGENS AGAINST HEPATITIS C VIRUS||08.05.2014||
|PCT/CU2013/000006||CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA||DUEÑAS CARRERA, Santiago|
The invention relates to chimeric vaccine antigens against hepatitis C virus (HCV), comprising selected regions of different antigens of said virus, which are placed in a pre-determined order inside the polypeptide. In addition, said chimeric antigens can include artificially-formed specific epitopes for auxiliary T cells. The chimeric antigens, and the resulting vaccine compositions, are suitable for use in medicine and the pharmaceutical industry, as well as being suitable for prophylactic and/or therapeutic use against HCV. The vaccine compositions of the invention generate a powerful, broad-spectrum immune response against different antigens of the virus, with a minimum number of components.
|7.||WO||WO/2014/044230 - METHOD FOR OBTAINING 1-KESTOSE||27.03.2014||
|PCT/CU2013/000005||CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA||PÉREZ CRUZ, Enrique, Rosendo|
The invention relates to a method for obtaining 1-kestose on an industrial scale, using a recombinant fructosyltransferase (FTF) isolated from Festuca arundinacea, constitutively expressed in a non saccharolytic yeast host. According to the invention, the recombinant FTF of the sucrose:sucrose 1-fructosyltransferase (1-SSTrec) type is produced in a constitutive and stable manner and in high yields, both in the supernatant and in the cell sediment of the culture of a strain of Pichia pastoris. The invention also relates to a method for obtaining 1-SST on an industrial scale. The resulting recombinant enzyme is used for the mass enzymatic production of fructooligosaccharides (FOS), specifically 1-kestose, from sucrose. The method of the invention allows FOS conversion percentages greater than 55%, with 1-kestose being represented in more than 90%.
|8.||WO||WO/2014/019555 - VESICLES WHICH INCLUDE EPIDERMAL GROWTH FACTOR AND COMPOSITIONS THAT CONTAIN SAME||06.02.2014||
|PCT/CU2013/000004||CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA||SANTANA MILIÁN, Héctor, Jesús|
The invention relates to vesicles which include epidermal growth factor (EGF), a cationic surface-active agent, and cholesterol or the derivatives thereof. The invention also discloses a method for preparing same using compressed fluid technology (FCs). The vesicles of the invention are useful in the production of drugs and cosmetic products, as well as in tissue engineering.
|9.||WO||WO/2013/189467 - COMPOUNDS FROM THE FRUITS OF ACROCOMIA CRISPA AND ACROCOMIA ACULEATA AGAINST INFLAMMATION AND OXIDATIVE STRESS||27.12.2013||
|PCT/CU2013/000003||CENTRO NACIONAL DE INVESTIGACIONES CIENTIFICAS (CNIC)||GONZALES CANAVACIOLO, Victor Luis|
The invention relates to obtaining a novel active ingredient and to the method for obtaining same from the unripe or ripe fruits of Acrocomia crispa and/or Acrocomia aculeata, both from the Arecaceae family. The active ingredient can be used as a nutritional supplement, in cosmetic-therapeutic formulations or in pharmaceutical compositions for preventing and/or treating oxidative stress and inflammation. The ingredient includes a mixture of fatty acids (free and/or as acylglycerols or ethyl esters) having between 6 and 28 carbon atoms, mostly linear chain saturated having 8, 10, 12, 14, 16 and 18 carbon atoms and unsaturated having 16 and 18 carbon atoms. Said ingredient can also contain sterols and fatty alcohols having a high molecular weight.
|10.||WO||WO/2013/143508 - METHOD FOR SIMULTANEOUS DETECTION, RECOVERY, IDENTIFICATION AND COUNTING OF MICROORGANISMS AND DEVICES FOR THE IMPLEMENTATION OF SAID METHOD||03.10.2013||
|PCT/CU2013/000002||CENTRO NACIONAL DE BIOPREPARADOS (BIOCEN)||RODRÍGUEZ MARTÍNEZ, Claudio|
The present invention describes a method and devices for the simultaneous detection, recovery, identification and counting of a plurality of microorganisms consisting in providing mixtures of nutrients specially selected from those that curtail the lag phase of growth in bacteria and moulds and which, together with fluorescent enzymatic, chromogenic or bioluminescent markers and other nutrient components or growth inhibitors, are embedded in three-dimensional structures or natural or artificial clays or ceramics with cavities of different dimensions and forms and specific surface areas of between 2 × 103 and 6 × 108 m2/m3.